tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ACRV Stock Latest News

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
Press ReleasesAcrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
2M ago
ACRV
Acrivon Therapeutics price target raised to $22 from $20 at H.C. Wainwright
PremiumThe Fly
Acrivon Therapeutics price target raised to $22 from $20 at H.C. Wainwright
2M ago
ACRV
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
PremiumPress Releases
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
2M ago
ACRV
Acrivon Therapeutics reports Q1 EPS (73c), consensus (84c)
PremiumThe Fly
Acrivon Therapeutics reports Q1 EPS (73c), consensus (84c)
2M ago
ACRV
Acrivon Therapeutics downgraded to Neutral from Buy at Ladenburg
PremiumThe Fly
Acrivon Therapeutics downgraded to Neutral from Buy at Ladenburg
3M ago
ACRV
Acrivon Therapeutics price target raised to $25 from $18 at BMO Capital
PremiumThe FlyAcrivon Therapeutics price target raised to $25 from $18 at BMO Capital
3M ago
ACRV
Acrivon Therapeutics price target lowered to $22 from $26 at JonesResearch
PremiumThe Fly
Acrivon Therapeutics price target lowered to $22 from $26 at JonesResearch
3M ago
ACRV
Acrivon Therapeutics Inc trading resumes
PremiumThe Fly
Acrivon Therapeutics Inc trading resumes
3M ago
ACRV
Acrivon Therapeutics Inc trading halted, volatility trading pause
PremiumThe Fly
Acrivon Therapeutics Inc trading halted, volatility trading pause
3M ago
ACRV
Acrivon Therapeutics price target raised to $30 from $26 at Piper Sandler
PremiumThe Fly
Acrivon Therapeutics price target raised to $30 from $26 at Piper Sandler
3M ago
ACRV
Acrivon Therapeutics price target raised to $17 from $14 at JMP Securities
PremiumThe Fly
Acrivon Therapeutics price target raised to $17 from $14 at JMP Securities
3M ago
ACRV
Acrivon Therapeutics Reports Breakthrough Results and Solid Finances
PremiumCompany Announcements
Acrivon Therapeutics Reports Breakthrough Results and Solid Finances
3M ago
8K
ACRV
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
PremiumPress ReleasesAcrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
3M ago
ACRV
Acrivon data for ACR-368 and pipeline program progress presented at event
PremiumThe Fly
Acrivon data for ACR-368 and pipeline program progress presented at event
3M ago
ACRV
Acrivon Therapeutics to hold a virtual research and development event
PremiumThe Fly
Acrivon Therapeutics to hold a virtual research and development event
3M ago
ACRV
Acrivon Therapeutics to hold a virtual research and development event
PremiumThe Fly
Acrivon Therapeutics to hold a virtual research and development event
3M ago
ACRV
Fly Insider: Steel Connect, Apple among week’s notable insider trades
PremiumThe Fly
Fly Insider: Steel Connect, Apple among week’s notable insider trades
3M ago
ELF
RXO
Acrivon Therapeutics files to sell 15.295M shares of common stock for holders
PremiumThe Fly
Acrivon Therapeutics files to sell 15.295M shares of common stock for holders
3M ago
ACRV
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
PremiumPress Releases
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
3M ago
ACRV
Acrivon Therapeutics presents data at AACR meeting
PremiumThe FlyAcrivon Therapeutics presents data at AACR meeting
3M ago
ACRV
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
PremiumPress Releases
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
3M ago
ACRV
Acrivon Therapeutics Secures $130M for Drug Development Expansion
PremiumCompany Announcements
Acrivon Therapeutics Secures $130M for Drug Development Expansion
3M ago
8K
ACRV

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >